Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Show Description +

Arshad M. Khanani, MD, MA, shares the case of a patient with long-standing wet AMD who had experienced complications of tachyphylaxis related to available anti-VEGF agents around the time that brolucizumab (Beovu, Novartis) was approved for marketing in the United States. How did this patient, who had a history of intraocular inflammation, fare on brolucizumab therapy?

Posted: 8/05/2021

Keywords:

Inflammation

brolucizumab

Wet AMD

Anti-VEGF

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA, shares the case of a patient with long-standing wet AMD who had experienced complications of tachyphylaxis related to available anti-VEGF agents around the time that brolucizumab (Beovu, Novartis) was approved for marketing in the United States. How did this patient, who had a history of intraocular inflammation, fare on brolucizumab therapy?

Posted: 8/05/2021

Keywords:

Inflammation

brolucizumab

Wet AMD

Anti-VEGF

Please log in to leave a comment.

Listen as a Podcast

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now